背景：可溶性IL-2受体是由活化的单核细胞上特异的亲和性膜受体释放的。在自身免疫性疾病、恶性肿瘤、感染性疾病、免疫缺陷等疾病患者的血清中发现有该物质水平升高。但是目前在AIP患者中没有其水平升高的报道。方法：采用ELISA法检测血清可溶IL-2受体的浓度。将自身免疫性胰腺炎患者血清可溶性IL-2受体浓度与可溶性IgG4相对比，并将激素治疗前后可溶性IL-2受体的水平做比较。结果：对于自身免疫性胰腺炎，可溶IL-2受体的敏感性与目前最好的标记物IgG4是相当的。此外，可溶IL-2受体血清水平在激素治疗后显著降低。结论：sIL-2R的血清水平与AIP相关的系统损伤数量有显著的相关性，此外，可溶性IL-2受体被认为是一种有效评估自身免疫性胰腺炎自身免疫活性的血清学标记物。

吉林大学第一医院肝胆胰内科  朱杰  摘译

本文首次发表于[Pancreas, Volume 41, Number 3, April 2012]

Soluble IL-2 Receptor(sIL-2R), a New Marker for Autoimmune Pancreatitis（AIP）

Background:

sIL-2R is released from its specific affinity membrane receptor on activated mononuclear cells. A high level of serum sIL-2R is recognized in cases with autoimmune diseases and malignancies, infectious diseases, immunodeficiency, however, so far, not reported in cases with AIP.

Methods:

Measurement of serum sIL-2R was done by ELISA method. Comparing with the level of sIgG4, and also by comparing between before and after the steroid therapy for AIP.

Results:

For AIP，the sensitivity of sIL-2R was equal to current best marker, IgG4.In addition, serum sIL-2R was significantly reduced, paralleling with steroid therapy.

Conclusion:

Together with the strong correlation between serum sIL-2R and the number of systemic lesions associated with AIP , sIL-2R is thought to be a potent serological marker for assessing autoimmune activity of AIP.